AR119979A1 - Anticuerpos contra el factor de las células madre y métodos de uso de ellas - Google Patents
Anticuerpos contra el factor de las células madre y métodos de uso de ellasInfo
- Publication number
- AR119979A1 AR119979A1 ARP200102566A ARP200102566A AR119979A1 AR 119979 A1 AR119979 A1 AR 119979A1 AR P200102566 A ARP200102566 A AR P200102566A AR P200102566 A ARP200102566 A AR P200102566A AR 119979 A1 AR119979 A1 AR 119979A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- antibodies
- factor
- stem cells
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900927P | 2019-09-16 | 2019-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119979A1 true AR119979A1 (es) | 2022-01-26 |
Family
ID=74868426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102566A AR119979A1 (es) | 2019-09-16 | 2020-09-16 | Anticuerpos contra el factor de las células madre y métodos de uso de ellas |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US20220324957A1 (enExample) |
| EP (3) | EP4650367A3 (enExample) |
| JP (4) | JP7717687B2 (enExample) |
| KR (1) | KR20220079561A (enExample) |
| CN (2) | CN114729036B (enExample) |
| AR (1) | AR119979A1 (enExample) |
| AU (2) | AU2020351138A1 (enExample) |
| BR (1) | BR112022004776A2 (enExample) |
| CA (2) | CA3154648A1 (enExample) |
| CL (1) | CL2022000633A1 (enExample) |
| CO (1) | CO2022003661A2 (enExample) |
| DK (1) | DK4031569T3 (enExample) |
| DO (1) | DOP2022000058A (enExample) |
| EC (1) | ECSP22022676A (enExample) |
| ES (1) | ES3053942T3 (enExample) |
| FI (1) | FI4031569T3 (enExample) |
| IL (1) | IL291385A (enExample) |
| MX (1) | MX2022003159A (enExample) |
| PE (1) | PE20230090A1 (enExample) |
| PH (1) | PH12022550647A1 (enExample) |
| PL (1) | PL4031569T3 (enExample) |
| PT (1) | PT4031569T (enExample) |
| SA (1) | SA522431966B1 (enExample) |
| TW (1) | TWI875812B (enExample) |
| UA (1) | UA129546C2 (enExample) |
| UY (1) | UY38883A (enExample) |
| WO (2) | WO2021055408A1 (enExample) |
| ZA (1) | ZA202203272B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US20220324957A1 (en) | 2019-09-16 | 2022-10-13 | Opsidio, LLC | Anti-stem cell factor antibodies and methods of use thereof in renal disease |
| KR20250167153A (ko) * | 2023-03-03 | 2025-11-28 | 셀덱스 쎄라퓨틱스, 인크. | 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물 |
| WO2026079764A1 (ko) * | 2024-10-10 | 2026-04-16 | 아주대학교산학협력단 | 마우스 scf를 중화하는 항체 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7144731B2 (en) * | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
| HUT62011A (en) * | 1989-10-16 | 1993-03-29 | Amgen Inc | Process for producing factors influencing the functioning of stem cells |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5911988A (en) | 1995-04-28 | 1999-06-15 | Bayer Corporation | Method for treating asthma using SCF antibody |
| JP3583214B2 (ja) | 1995-12-01 | 2004-11-04 | 株式会社ニチレイ | ヒトｓｃｆに対するモノクローナル抗体 |
| US20090087878A9 (en) | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| DK2383295T3 (en) | 2003-12-10 | 2015-06-15 | Squibb & Sons Llc | Ip-10 antibodies and uses thereof |
| RU2407752C2 (ru) | 2004-04-29 | 2010-12-27 | Оцука Фармасьютикал Ко., Лтд. | Антитела к гликопротеину vi и способы продуцирования и использования этих антител |
| WO2006002064A2 (en) | 2004-06-14 | 2006-01-05 | Aerovance, Inc. | Antibody inhibiting stem cell factor activity and use for treatment of asthma |
| US20080248050A1 (en) | 2006-06-30 | 2008-10-09 | Uchicago Argonne, Llc | Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine |
| WO2009127046A1 (en) | 2008-04-14 | 2009-10-22 | Proscan Rx Pharma Inc. | Prostate specific membrane antigen antibodies and antigen binding fragments |
| KR20200023495A (ko) | 2011-01-10 | 2020-03-04 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 줄기 세포 인자 억제제 |
| KR101384360B1 (ko) | 2012-05-04 | 2014-04-14 | 아주대학교산학협력단 | Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| WO2015006554A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
| US10927153B1 (en) | 2015-05-20 | 2021-02-23 | University Of South Florida | Synthetic plasmodium antigens, compositions, and uses thereof |
| EP3337827B1 (en) | 2015-08-19 | 2026-07-08 | Pfizer Inc. | Tissue factor pathway inhibitor antibodies and uses thereof |
| KR20170022409A (ko) | 2015-08-20 | 2017-03-02 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| US11091559B2 (en) * | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
| MX2018007818A (es) | 2015-12-22 | 2019-07-01 | Abbvie Stemcentrx Llc | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. |
| TWI773693B (zh) | 2016-10-05 | 2022-08-11 | 新加坡商細胞研究私人有限公司 | 從臍帶的羊膜分離間質幹細胞的方法、從臍帶的羊膜分離的間質幹細胞群以及用於從臍帶的羊膜分離間質幹細胞的細胞培養基 |
| WO2019066093A1 (ko) | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| WO2019088658A1 (ko) | 2017-10-31 | 2019-05-09 | 주식회사 컴워스파마 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| KR102131898B1 (ko) | 2017-10-31 | 2020-07-08 | 주식회사 노벨티노빌리티 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| CN120305401A (zh) | 2018-10-19 | 2025-07-15 | 总医院公司 | 用于肝病的治疗的组合物和方法 |
| US20220324957A1 (en) | 2019-09-16 | 2022-10-13 | Opsidio, LLC | Anti-stem cell factor antibodies and methods of use thereof in renal disease |
| JP2024511027A (ja) | 2021-03-17 | 2024-03-12 | オプシディオ， エルエルシー | 幹細胞因子抗体及びその使用方法 |
-
2020
- 2020-09-16 US US17/640,544 patent/US20220324957A1/en active Pending
- 2020-09-16 US US17/640,538 patent/US20220340655A1/en not_active Abandoned
- 2020-09-16 PT PT208665307T patent/PT4031569T/pt unknown
- 2020-09-16 AU AU2020351138A patent/AU2020351138A1/en active Pending
- 2020-09-16 AR ARP200102566A patent/AR119979A1/es unknown
- 2020-09-16 UA UAA202201048A patent/UA129546C2/uk unknown
- 2020-09-16 FI FIEP20866530.7T patent/FI4031569T3/fi active
- 2020-09-16 EP EP25193246.3A patent/EP4650367A3/en active Pending
- 2020-09-16 JP JP2022517173A patent/JP7717687B2/ja active Active
- 2020-09-16 CA CA3154648A patent/CA3154648A1/en active Pending
- 2020-09-16 TW TW109131936A patent/TWI875812B/zh active
- 2020-09-16 ES ES20866530T patent/ES3053942T3/es active Active
- 2020-09-16 PL PL20866530.7T patent/PL4031569T3/pl unknown
- 2020-09-16 WO PCT/US2020/050973 patent/WO2021055408A1/en not_active Ceased
- 2020-09-16 DK DK20866530.7T patent/DK4031569T3/da active
- 2020-09-16 MX MX2022003159A patent/MX2022003159A/es unknown
- 2020-09-16 PH PH1/2022/550647A patent/PH12022550647A1/en unknown
- 2020-09-16 CN CN202080078693.XA patent/CN114729036B/zh active Active
- 2020-09-16 PE PE2022000419A patent/PE20230090A1/es unknown
- 2020-09-16 EP EP20865210.7A patent/EP4031176A4/en active Pending
- 2020-09-16 CA CA3154649A patent/CA3154649A1/en active Pending
- 2020-09-16 EP EP20866530.7A patent/EP4031569B1/en active Active
- 2020-09-16 BR BR112022004776A patent/BR112022004776A2/pt unknown
- 2020-09-16 JP JP2022517136A patent/JP7698635B2/ja active Active
- 2020-09-16 CN CN202410508865.2A patent/CN118561997A/zh active Pending
- 2020-09-16 AU AU2020348295A patent/AU2020348295A1/en active Pending
- 2020-09-16 US US17/022,465 patent/US11939373B2/en active Active
- 2020-09-16 UY UY0001038883A patent/UY38883A/es active IP Right Grant
- 2020-09-16 WO PCT/US2020/050974 patent/WO2021055409A1/en not_active Ceased
- 2020-09-16 KR KR1020227012536A patent/KR20220079561A/ko active Pending
-
2022
- 2022-03-15 DO DO2022000058A patent/DOP2022000058A/es unknown
- 2022-03-15 IL IL291385A patent/IL291385A/en unknown
- 2022-03-15 CL CL2022000633A patent/CL2022000633A1/es unknown
- 2022-03-16 SA SA522431966A patent/SA522431966B1/ar unknown
- 2022-03-18 ZA ZA2022/03272A patent/ZA202203272B/en unknown
- 2022-03-24 EC ECSENADI202222676A patent/ECSP22022676A/es unknown
- 2022-03-28 CO CONC2022/0003661A patent/CO2022003661A2/es unknown
- 2022-09-06 US US17/929,976 patent/US20230019680A1/en not_active Abandoned
-
2023
- 2023-11-02 US US18/500,622 patent/US12410246B2/en active Active
-
2025
- 2025-06-13 JP JP2025099435A patent/JP2025125563A/ja active Pending
- 2025-07-23 JP JP2025123268A patent/JP2025165991A/ja active Pending
- 2025-08-06 US US19/292,452 patent/US20260193336A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22022676A (es) | Anticuerpos contra el factor de las células madre y métodos de uso de ellos | |
| MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
| MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
| DOP2021000101A (es) | Anticuerpos humanizados contra c-kit | |
| BR112022007284A2 (pt) | Inibição de integrina humana alpha-4 beta-7 | |
| MX2018007089A (es) | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| MX2022014761A (es) | Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso. | |
| NI201200171A (es) | Anticuerpos hacia gdf8 humano | |
| CL2008003361A1 (es) | Anticuerpos monoclonales que se unen al hgm-csf y las composicones medias que los comprenden. | |
| ECSP20039728A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos | |
| PT3927370T (pt) | Métodos para produção de células t autólogas para tratar cancros e composições destas | |
| MX2020013428A (es) | Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana. | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
| MX2021007718A (es) | Anticuerpos monoclonales que se unen especificamente a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso. | |
| MX2016013686A (es) | Anticuerpos de antigeno anti-tf humanizado. | |
| WO2020089396A3 (en) | Composition and methods of treating inflammatory and autoimmune diseases | |
| CL2023002968A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| AR117565A1 (es) | Agentes de unión a c3 y método de uso de los mismos | |
| CL2024000829A1 (es) | Formas sólidas de un inhibidor ge glyt1 | |
| DOP2024000117A (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| AR097038A1 (es) | Uso de un ligando de cd6 y método basado en el | |
| CL2022001677A1 (es) | Anticuerpos anti-ccl2 biespecíficos | |
| CO2023015859A2 (es) | Anticuerpos para tratar alfa-sinucleinopatías |